Literature DB >> 8956038

Ornithine transcarbamylase deficiency: characterization of gene mutations and polymorphisms.

E O Oppliger Leibundgut1, B Wermuth, J P Colombo, S Liechti-Gallati.   

Abstract

We identified three new and three known mutations in male patients with OTC deficiency using PCR amplification of all the individual exons, including the adjacent intron sequences, followed by direct sequencing of the amplimers. Two mutations were found in males presenting with neonatal fatal hyperammonemia and no detectable enzyme activity in their livers. The H302Y mutation found in one patient affects the putative binding site for ornithine. The second patient had an R141X mutation, which is one of the few recurrent mutations in the OTC gene. Four different missense mutations were identified in male patients with late onset of the disease and residual OTC activities between 14% and 35%. The mutations are Y176C and P220A and the known mutations K88N and T343K, respectively. Four of the patients' mothers were identified as carriers. In two cases, the mutations had occurred spontaneously. In addition, the frequency of four polymorphisms of the OTC gene was studied. The K46R polymorphism in exon 2 and the Q27OR polymorphism in exon 8 were found in 36% and 4% of screened alleles, respectively. Two questionable polymorphisms in exon 4, F101L and L111P, were not present in any of the screened alleles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8956038     DOI: 10.1002/(SICI)1098-1004(1996)8:4<333::AID-HUMU6>3.0.CO;2-8

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  5 in total

1.  Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes.

Authors:  Scott N Ashley; Suryanarayan Somanathan; Christian Hinderer; Maxwell Arias; Deirdre McMenamin; Christine Draper; James M Wilson
Journal:  J Immunol       Date:  2017-05-12       Impact factor: 5.422

2.  Under recognition of late onset ornithine transcarbamylase deficiency.

Authors:  R E Schultz; M K Salo
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

3.  Estimation of the total number of disease-causing mutations in ornithine transcarbamylase (OTC) deficiency. Value of the OTC structure in predicting a mutation pathogenic potential.

Authors:  J A Arranz; E Riudor; C Marco-Marín; V Rubio
Journal:  J Inherit Metab Dis       Date:  2007-03-01       Impact factor: 4.750

4.  Probing remote residues important for catalysis in Escherichia coli ornithine transcarbamoylase.

Authors:  Lisa Ngu; Jenifer N Winters; Kien Nguyen; Kevin E Ramos; Nicholas A DeLateur; Lee Makowski; Paul C Whitford; Mary Jo Ondrechen; Penny J Beuning
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

5.  Therapeutic enzyme engineering using a generative neural network.

Authors:  Athanasios Dousis; Kanchana Ravichandran; Kevin Smith; Andrew Giessel; Sreyoshi Sur; Iain McFadyen; Wei Zheng; Stuart Licht
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.